The LC-HRMS method for SCFA analysis is described in detail in the Supplementary Material
This is more common with oral supplementation at doses above 2,000 mg daily
Rotigotine is a dopamine agonist, which has promising potential for the treatment of PD [188], but its use is challenging due to the low bioavailability and high first-pass effects after oral administration, as well as application-site reactions after transdermal treatment [189]
Chan, A., Paskavitz, J., Remington, R., Rasmussen, S., and Shea, T
I dont necessarily like this area because there is a small chance (very small) of nerve damage (1)